[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"highly-active-antiretroviral-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:highly-active-antiretroviral-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100374822","study-of-autophagy-and-the-effects-of-galig-gene-products-in-hiv-1-infected-patients-who-are-under-antiretroviral-therapy-since-primary-infection-chronic-phase-or-never-treated-100374822",false,"NCT04160455","Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.","ATGALIG-HIV","Inclusion Criteria:\n\nGeneral criteria:\n\n* Age \\>=18 years\n* Man or woman\n* Infected with HIV-1 (and not co-infected with HIV-2)\n* Followed at Orleans' Regional Hospital\n* Patient belonging to one of the predefined cohorts\u002Fgroups (see below)\n* Patient having provided a written consent\n\nSpecific profiles of HIV-infected patients for the ATGALIG-HIV study:\n\nCohort A: patients on suppressive antiretroviral therapy (HIV RNA \\\u003C50 copies \u002F ml for at least 4 years) initiated during the chronic phase, divided into 2 groups according to the following criteria:\n\n* group A1: CD4 count less than 500 cells \u002F ml at the time of inclusion in the study\n* group A2: CD4 count above 500 cells \u002F ml at the time of inclusion in the study Cohort B: patients on suppressive antiretroviral therapy (HIV RNA \\\u003C50 copies \u002F ml for at least 4 years) initiated since the primary-infection (within 4 months after acute infection)\n\nCohort C: patients with detectable HIV RNA, naïve of antiretroviral, but who have an indication to start antiretroviral therapy, divided into the following 3 groups:\n\n* group C1: HIV diagnosis made during primary infection (within 4 months of infection)\n* group C2: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count above 200 cells\u002Fml at the time of inclusion in the study\n* group C3: HIV diagnosis made during the chronic phase (more than 1 year after contamination), with CD4 count less than 200 cells\u002Fml at the time of inclusion in the study Cohort D: patients who have undetectable plasma HIV RNA (HIV RNA \\\u003C50 copies \u002F ml ) without antiretroviral therapy, either spontaneously (HIV controllers or elite controllers) or after treatment interruption (post-treatment controllers)\n\nExclusion Criteria:\n\n* Patient unable, according to the investigator, to meet the requirements of the protocol\n* Pregnant or lactating woman\n* Patient with a history of inflammatory bowel disease, malignancy, intestinal ischemia, malabsorption or other gastrointestinal dysfunction that, in the judgment of the investigator, could interfere with the interpretation of the results.\n* Presence of coagulation abnormality or unexplained bleeding history\n* Treatment with oral or injectable anticoagulant (curative or preventive)\n* Patient covered by Article L.1121-5 to L.1121-8 and L.1122-1-2 of the French Public Health Code (including minors and protected adults)\n* Patient under guardianship or curatorship\n* Patient who uncovered by French health insurance Patient participating in another clinical trial, evaluating a treatment","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","OBSERVATIONAL","Little is known about autophagy during HIV infection. Recently, two different teams reported important dysfunctions of autophagy in HIV-infected patients despite sustained suppressive antiretroviral therapy. As altered autophagy is strongly linked to cellular senescence and chronic inflammation, two hallmarks of HIV-infected patients despite long-term suppressive antiretroviral therapy, it is important to improve our knowledge in the area.\n\nOur main objective is to determine whether all or part of mononuclear cell subpopulations (CD4+ and CD8+ T lymphocytes, and monocytes) exhibit a defect in autophagy function in a cohort of HIV-infected patients who are virologically-controlled (plasma HIV RNA \\\u003C50 copies \u002F ml) either spontaneously (i.e. HIV controllers or post-treatment controllers) or after they started antiretroviral therapy at different time points (i.e. at the acute or chronic phases), as compared with a control group (i.e. uninfected healthy blood donors).",[24,25,26,27],"Autophagy","Galectins","HIV Infections","Highly Active Antiretroviral Therapy",[29,30,31,32,33],"Antiretroviral therapy","basal autophagy","GALIG gene","HIV","apoptosis","RECRUITING","2025-12-22",{"date":37,"type":38},"2025-12-30","ACTUAL",{"date":40,"type":38},"2019-11-07",{"date":42,"type":20},"2039-11-07",{"name":44,"class":45},"Centre Hospitalier Régional d'Orléans","OTHER"]